FERMENTATION LEVEL CULTIVATION OF BORDETELLA PERTUSSIS
US Application 06/889,621
Filed on 1986-07-28
Filed on 1986-07-28
NOVEL METHOD OF PREPARING TOXOID BY OXIDATION AND METAL IONS
US Patent 4,762,710
Filed on 1986-06-16
Filed on 1986-06-16
Biologically Pure, Prohormone Converting Enzyme and Synthesis of Peptide Hormones.
US Application 06/874,633
Filed on 1986-06-16
Filed on 1986-06-16
TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK
US Application 06/849,815
Filed on 1986-04-09
Filed on 1986-04-09
NON-INVASIVE OPTICAL ASSESMENT OF PLATELET VIABILITY
US Patent 4,522,494
Filed on 1982-07-07
Filed on 1982-07-07
Hydrocephalic Antenatal Vent For Intrauterine Treatment (HAVIT)
US Patent 4,413,985
Filed on 1981-11-30
Filed on 1981-11-30
Nondenaturing Zwitterionic Detergents
US Patent 4,372,888
Filed on 1981-08-19
Filed on 1981-08-19
NONDENATURING ZWITTERIONIC DETERGENTS FOR MEMBRANE BIOCHEMISTRY
US Application 06/181,465
Filed on 1980-08-26
Filed on 1980-08-26
SOLID PHASE SYNTHESIS OF PEPTIDES WITH CARBOXYL-TERMINAL AMIDES
US Patent 3,988,307
Filed on 1974-09-06
Filed on 1974-09-06
Treatment of Niemann-Pick Disease Type-C with 2-hydroxypropyl-β-cyclodextrin
Currently, there are no FDA-approved therapies for Niemann-Pick disease type-C1 (NPC). NPC is a rare lethal genetic lysosomal storage disorder that results in an accumulation of cholesterol in the liver and spleen and eventually leads to neurodegeneration. 2-hydroxypropyl-β-cyclodextrin (HPβCD) is a cyclodextrin typically used by the pharmaceutical industry as an excipient. Studies of NPC in animal models have shown that HPβCD can reduce the biochemical burden associated with NPC, improving neurological pathology, decreasing neurological dysfunction, and increasing lifespan.